Patient relevant endpoints in oncology: Current issues in the context of early benefit assessment in Germany

Health Economics Review

Volumn 4, Issue 1, 2014, Pages 1-8

  Dabisch, Inna ^a   Dethling, Jürgen ^b   Dintsios, Charalabos Markos ^a   Drechsler, Melanie ^c   Kalanovic, Daniel ^d   Kaskel, Peter ^e   Langer, Frank ^f   Ruof, Jörg ^g   Ruppert, Thorsten ^a   Wirth, Daniel ^h  

^a VFA DIE FORSCHENDEN PHARMA UNTERNEHMEN   (Germany)

^b Glaxo Smith Kline GmbH and Co KG   (Germany)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^d PFIZER INC   (United States)

^e MSD Sharp and Dohme GmbH   (Germany)

^f LILLY DEUTSCHLAND GMBH   (Germany)

^g ROCHE INNOVATION CENTER MUNICH   (Germany)

^h JANSSEN CILAG GMBH   (Germany)

Author keywords

AMNOG; Endpoints; German health care reform; Oncology; Patient relevant benefit; Progression free survival

Indexed keywords

IMATINIB;

CANCER SURGERY; EARLY BENEFIT ASSESSMENT; GERMANY; HEALTH CARE CONCEPTS; HEALTH CARE POLICY; HUMAN; INFORMATION DISSEMINATION; MEDICAL ETHICS; MEDICAL INFORMATION; MEDICAL SOCIETY; MORBIDITY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE;

EID: 84971317620     PISSN: None     EISSN: 21911991     Source Type: Journal    
DOI: 10.1186/2191-1991-4-2     Document Type: Review

References (42)

1. Soria JC, Massard C, Le Chevalier T: Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 2010, 21:2324-2332.
2. Oncology Working Party: Guideline on the evaluation of anticancer medicinal products in man, EMA/CHMP/205/95/Rev.4. London, UK: European Medical Agency. http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2011/12/WC500119966.pdf; 2012. Accessed 28 March 2013.
3. Bundesinstitut für Arzneimittel und Medizinprodukte: German Medicinal Products Act: Non-official translation. Berlin, Germany: Bundesinstitut für Arzneimittel und Medizinprodukte. http://hh.juris.de/englisch_amg/index. html; 2011. Accessed 28 March 2013.
4. Marckmann G, Meran JG, Year books of the Working Group of Medical Ehics Committees in the Federal Republic of Germany Issue 13: Ethical aspects of research in oncology. Cologne, Germany: Deutscher Ärzte-Verlag; 2007.
5. Yothers G: Toward progression-free survival as a primary end point in advanced colorectal cancer. J Clin Oncol 2007, 25:5153-5154.
6. NN: Directive 2001/20/EC of the European parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Communities. L_121/34 http:// eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2001:121:0034:0044:en: PDF; 2011. Accessed 19 April 2013.
7. Brück P, Pierzchlewska M, Kaluzna-Oleksy M, Ramos Lopez ME, Rummel M, Hoelzer D, Böhme A: Dying of hematologic patients-treatment characteristics in a German University Hospital. Support Care Cancer 2012, 20:2895-2902.
8. Ricevuto E, Bruera G, Marchetti P: General principles of chemotherapy. Eur Rev Med Pharmacol Sci 2010, 14:269-271.
9. McKee AE, Farrell AT, Pazdur R, Woodcock J: The role of the U.S. food and drug administration review process: clinical trial endpoints in oncology. Oncologist 2010, 15(Suppl 1):13-18.
10. Di Leo A, Bleiberg H, Buyse M: Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 2003, 21:2045-2047.
11. Markman M: Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials. Gynecol Oncol 2007, 106:279-281.
12. Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R: Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 2012, 119:5963-5971.
13. Pagani O, Senkus E, Wood W, Colleoni M, Cufer T, Kyriakides S, Costa A, Winer EP, Cardoso F, ESO-MBC Task Force: International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010, 102:456-463.
14. Goodin DS, Reder AT: Evidence-based medicine: promise and pitfalls. Mult Scler 2012, 18:947-948.
15. Gronseth GS, Ashman E: The AAN response to evidence-based medicine: promise and pitfalls. Mult Scler 2012, 18:949-950.
16. Broglio KR, Berry DA: Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009, 101:1642-1649.
17. Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P: Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008, 26:1987-1992.
18. NN: German social code, section 27 paragraph 1. [in German] http://www. sozialgesetzbuch-sgb.de/sgbv/27.html Accessed 19 April 2013.
19. Sountoulides P, Metaxa L, Cindolo L: Atypical presentations and rare metastatic sites of renal cell carcinoma: a review of case reports. J Med Case Rep 2011, 5:429.
20. Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, et al: Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 2012, 23:973-980.
21. Kramer MWMA, Peters I, Waalkes S, Kuczyk MA: Systemic and surgical management of metastatic renal cell carcinoma: article in German. Urologe A 2012, 51:217-225.
22. Ljungberg B, Alamdari FI, Rasmuson T, Roos G: Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999, 84:405-411.
23. Hotte SJ, Bjarnason GA, Heng DY, Jewett MA, Kapoor A, Kollmannsberger C, et al: Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. Curr Oncol 2011, 18(Suppl 2):S11-S19.
24. Herschbach P, Keller M, Knight L, Brandl T, Huber B, Henrich G, et al: Psychological problems of cancer patients: a cancer distress screening with a cancer-specific questionnaire. Br J Cancer 2004, 9:504-511.
25. Cella D, Escudier B, Rini B, Chen C, Bhattacharyya H, Tarazi J, Rosbrook B, Kim S, Motzer R: Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial. Br J Cancer 2013, 108:1571-1578.
26. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
27. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA, IRIS Investigators: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009, 23:1054-1061.
28. Ehninger G, Wörmann B: Benefit assessment from a German medical society's point of view [in German]. Berlin: German Society for Hematology and Oncology. http://www.dgho.de/informationen/nachrichten/Vortrag% 20Berlin%20GE%202012%20gekuerzt.pdf (2012) Accessed 02 August 2012.
29. Buettner R, Wolf J, Thomas RK: Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 2013. Epub ahead of print.
30. Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou YC, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011, 378:1931-1939.
31. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL: The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010, 127:2209-2221.
32. Mathews HF, Lannin DR, Mitchell JP: Coming to terms with advanced breast cancer: black women's narratives from eastern North Carolina. Soc Sci Med 1994, 38:789-800.
33. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, Von Minckwitz G, Buzdar AU, Smith IE, Symmans WF, Singh B, Winer EP: Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008, 26:814-819.
34. Silvestri G, Pritchard R, Welch HG: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. Brit Med J 1998, 317:771-7765.
35. Borner MM, Schoffski P, De Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, De Boer RF, Martin C, Fumoleau P: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer 2002, 38:349-358.
36. Thomas R, Godward S, Makris A, Bloomfield D, Moody AM, Williams M: Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. Clin Oncol (R Coll Radiol) 2004, 16:485-491.
37. Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D: Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the boniva alendronate trial in osteoporosis (BALTO). Curr Med Res Opin 2005, 2:1895-1903.
38. Twelves C, Gollins S, Grieve R, Samuel L: A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/ leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol 2006, 17:239-245.
39. Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH: Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 2012, 30:3998-4003.
40. Escudier BJ, Porta C, Bono B, De GU, Parikh O, Hawkins RE, Sevin E, Negrier S, Khan S, McCann L, Mehmud F, Cella D: Patient preference between pazopanib and sunitinib: results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC)-PISCES study, NCT 01064310. J Clin Oncol 2012, 30(May 20 Supplement):CRA450.
41. Großelfinger R, Herrmann-Frank A, Bender R, Kiefer C, Kromp M, Lange S: Stem cell transplantation in multiple myeloma: IQWiG Report N05-03C [in German]. IQWiG Reports 85:1-195. https://www.iqwig.de/download/N05-03C_Abschlussbericht_Stammzelltransplantation_bei_Multiplem_Myelom. pdf; 2011. Accessed 22 April 2013.
42. Mühlbacher AC, Nübling M: Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma. Eur J Health Econ 2011, 12:193-203.